Study On The Correlation Between The Expression Of Serum VEGF-165b In Patients With Advanced Colorectal Cancer And The Efficacy Of Bevacizumab

Objective To study the expression serum VEGF-A165 b levels in patients with metastatic colorectal cancer and investigate association between bevacizumab-related chemotherapy regimens and the expression serum VEGF-A165 b levels.Methods The 60 cases of metastatic colorectal cancer in Yan Tai Yu Huang Ding Affiliated Hospital of Qingdao University from November 2012 to August 2014 were divided into FOLFIRI treatment group(30 cases) and FOLFIRI+ bevacizumab treatment group(30 cases). The expression serum VEGF-165 b levels were analyzed by an enzyme-linked immunosorbent assay( ELISA). After three cycles of chemotherapy, the short-term response was evaluated. All the patients were followed-up, and the progression-free survival(PFS) was calculated.Results Serum levels of VEGF-165 b were significantly lower in patients with lymph node metastases than no lymph node metastases, there were statistically significant(p=0.03). Levels of VEGF-165 b did not correlated with clinical baseline characteristics, such as age, gender, performance status, localization, or KRAS type(P>0.05). 60 patients were evaluated the short-term response. In FOLFIRI + bevacizumab group, patients with lower levels of VEGF-165 b have a better efficacy, there were statistically significant(P=0.0277). However, in FOLFIRI group, there were no significant( P=0.7877). There were no significant differences in PFS among the two groups(P> 0.05).Conclusions The low levels VEGF-165 b was associated with lymph node metastasis, and the expression of VEGF-165 b was associated with bevacizumab efficacy, so pretreatment serum VEGF-A165 b levels were predictive for bevacizumab-based treatment benefit.